{"id":586036,"date":"2022-02-10T17:46:01","date_gmt":"2022-02-10T17:46:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=586036"},"modified":"2022-02-10T17:46:01","modified_gmt":"2022-02-10T17:46:01","slug":"hypoxic-ischemic-encephalopathy-market-disease-emerging-therapy-and-market-report-2032","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/hypoxic-ischemic-encephalopathy-market-disease-emerging-therapy-and-market-report-2032_586036.html","title":{"rendered":"Hypoxic ischemic encephalopathy Market Disease, Emerging Therapy, and Market Report 2032"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1644495591.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Hypoxic ischemic encephalopathy Market Disease, Emerging Therapy, and Market Report 2032\" src=\"https:\/\/www.abnewswire.com\/uploads\/1644495591.jpeg\" alt=\"Hypoxic ischemic encephalopathy Market Disease, Emerging Therapy, and Market Report 2032\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s Hypoxic Ischemic Encephalopathy Market Insights report provides a thorough understanding of current treatment practices, emerging drugs, Hypoxic Ischemic Encephalopathy market share of the individual therapies, current and forecasted Hypoxic Ischemic Encephalopathy market size from 2019 to 2032 segmented into 7MM (the USA, EU5 (the UK, Italy, Spain, France, and Germany), and Japan).<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Hypoxic Ischemic Encephalopathy Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Hypoxic-ischemic encephalopathy (HIE) is a serious and life-threatening type of newborn brain damage (brain dysfunction) that occurs when the brain doesn&#8217;t receive enough oxygen and blood flow for a period of time. As the name suggests, Hypoxic means, not enough oxygen; ischemic means not enough blood flow; and encephalopathy means brain disorder.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Download Sample Report<\/strong> @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/hypoxic-ischemic-encephalopathy-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\"><strong>Hypoxic Ischemic Encephalopathy Market<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of the Hypoxic Ischemic Encephalopathy Market Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>According to secondary findings, clinically, male infants are more vulnerable to neonatal HIE and suffer more long-term deficits than females. Clinical data shows that females have a substantial advantage over males, among infants at risk for HIE.<\/li>\n<li>Neonatal HIE is estimated to occur in about 1.5 per 1,000 live births. Among infants with moderate HIE, 10-20% develop minor neurological conditions, and 30-50% develop more serious complications.<\/li>\n<li>Hypoxic Ischemic Encephalopathy companies such as ReAlta Life Sciences, and several others.<\/li>\n<li>Hypoxic Ischemic Encephalopathy therapies such as RLS-0071, and several others.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Hypoxic Ischemic Encephalopathy Causes<\/strong><\/p>\n<p style=\"text-align: justify;\">The three major causes of neonatal deaths worldwide are infections (36%, which includes sepsis\/pneumonia, tetanus, and diarrhea), pre-term (28%), and birth asphyxia (23%). The development of HIE may occur during pregnancy, labor, and delivery or in the postnatal period. HIE can be caused by a variety of reasons or medical complications around the time of birth. In several cases, medical malpractice also plays a major role.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/hypoxic-ischemic-encephalopathy-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\"><strong>Hypoxic Ischemic Encephalopathy Symptoms<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\">HIE symptoms immediately after birth will vary significantly, often depend on the severity and extent of the brain injury, as well as the areas of the brain that were affected. Babies with HIE may exhibit any of the following signs: Missing reflexes, Breathing problems, Feeding problems, Low or high muscle tone, Seizures, Show signs of organ dysfunction, especially of the heart, lungs, kidneys, liver, and blood.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Hypoxic Ischemic Encephalopathy Diagnosis<\/strong><\/p>\n<p style=\"text-align: justify;\">For diagnosis purposes, if HIE is suspected, medical staff can conduct brain imaging, such as ultrasound and MRI, to see how severely tissue in the brain is damaged. Blood gas tests are done to determine the pH of the baby&rsquo;s blood, which can also provide some information about the baby&rsquo;s oxygen levels. Once brain damage is permanent, there is no cure for HIE.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/hypoxic-ischemic-encephalopathy-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\"><strong>Hypoxic Ischemic Encephalopathy Treatment<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\">Despite a multitude of studies, the ultimate pathogenesis of HIE remains unknown. HIE symptoms can be ambiguous and frequently overlap with other neurologic and metabolic disorders in newborns. Therefore, it is imperative to rule out life-threatening or treatable causes of these symptoms. Treatment can be separated into immediate\/hospital management and long-term treatment.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Hypoxic Ischemic Encephalopathy Market Insights<\/strong><\/p>\n<p style=\"text-align: justify;\">In moderate to severe HIE, it is very important that the child is properly monitored and treated. Effective medical care may significantly reduce the child&rsquo;s prognosis. The first several weeks are the most critical period for monitoring and treating a child with moderate to severe HIE. At present, there is no true cure for HIE. However, currently there is one treatment, called therapeutic hypothermia that can reduce the extent of permanent brain damage if given very shortly after birth or the oxygen-depriving incident. Most guidelines dictate that therapeutic hypothermia be given within six hours, although there may be some benefit up to 24 hours. Babies with severe HIE injuries will often need life-long support and accommodations.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Hypoxic Ischemic Encephalopathy Emerging Therapy Assessment<\/strong><\/p>\n<p style=\"text-align: justify;\">The dynamics of the Hypoxic Ischemic Encephalopathy (HIE) market are expected to improve in the next years as a result of the increase in R&amp;D and introduction of new medicines. Key companies such as ReAlta Life Sciences, Hope Biosciences, GW Pharmaceuticals, Chiesi, and others are developing innovative medicines for this indication, which will result in a considerable increase in the market size.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Get an overview of the report @<\/strong> <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/hypoxic-ischemic-encephalopathy-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\"><strong>Hypoxic Ischemic Encephalopathy Market Report<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Hypoxic Ischemic Encephalopathy Market Drivers<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Upsurge in the number of incident cases<\/li>\n<li>Regulatory incentives such as market exclusivity for orphan designated drugs<\/li>\n<li>More collaborative efforts of pharmaceutical companies, academia, and others<\/li>\n<li>Potential approval of emerging therapies<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Hypoxic Ischemic Encephalopathy Market Barriers<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Limited knowledge<\/li>\n<li>Lack of FDA-approved drugs<\/li>\n<li>Treatment barriers must be overcome in order for the market to expand.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request Sample Report<\/strong> @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/hypoxic-ischemic-encephalopathy-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\"><strong>Hypoxic Ischemic Encephalopathy Market Insights<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Content<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Key Insights<\/p>\n<p style=\"text-align: justify;\">2. Executive Summary of Hypoxic Ischemic Encephalopathy<\/p>\n<p style=\"text-align: justify;\">3. Competitive Intelligence Analysis for Hypoxic Ischemic Encephalopathy<\/p>\n<p style=\"text-align: justify;\">4. Hypoxic Ischemic Encephalopathy: Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">5. Hypoxic Ischemic Encephalopathy: Disease Background and Overview<\/p>\n<p style=\"text-align: justify;\">6. Patient Journey<\/p>\n<p style=\"text-align: justify;\">7. Hypoxic Ischemic Encephalopathy Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\">8. Treatment Algorithm, Current Treatment, and Medical Practices<\/p>\n<p style=\"text-align: justify;\">9. Hypoxic Ischemic Encephalopathy&nbsp;Unmet Needs<\/p>\n<p style=\"text-align: justify;\">10. Key Endpoints of Hypoxic Ischemic Encephalopathy Treatment<\/p>\n<p style=\"text-align: justify;\">11. Hypoxic Ischemic Encephalopathy&nbsp;Marketed Products<\/p>\n<p style=\"text-align: justify;\">12. Hypoxic Ischemic Encephalopathy&nbsp;Emerging Therapies<\/p>\n<p style=\"text-align: justify;\">13. Hypoxic Ischemic Encephalopathy: Seven Major Market Analysis<\/p>\n<p style=\"text-align: justify;\">14. Attribute analysis<\/p>\n<p style=\"text-align: justify;\">15. 7MM: Market Outlook<\/p>\n<p style=\"text-align: justify;\">16. Access and Reimbursement Overview of Hypoxic Ischemic Encephalopathy<\/p>\n<p style=\"text-align: justify;\">17. KOL Views<\/p>\n<p style=\"text-align: justify;\">18. Market Drivers<\/p>\n<p style=\"text-align: justify;\">19. Market Barriers<\/p>\n<p style=\"text-align: justify;\">20. Appendix<\/p>\n<p style=\"text-align: justify;\">21. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\">22. Disclaimer<\/p>\n<p style=\"text-align: justify;\">23. About DelveInsight<\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>About Us<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&amp;D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers &amp; Acquisitions.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Contact Us<\/strong><\/p>\n<p style=\"text-align: justify;\">Yash<\/p>\n<p style=\"text-align: justify;\">info@delveinsight.com<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56402.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Yash Bhardwaj<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=hypoxic-ischemic-encephalopathy-market-disease-emerging-therapy-and-market-report-2032\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304  S. Jones Blvd #2432<br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=hypoxic-ischemic-encephalopathy-market-disease-emerging-therapy-and-market-report-2032\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight&rsquo;s Hypoxic Ischemic Encephalopathy Market Insights report provides a thorough understanding of current treatment practices, emerging drugs, Hypoxic Ischemic Encephalopathy market share of the individual therapies, current and forecasted Hypoxic Ischemic Encephalopathy market size from 2019 to 2032 segmented into &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/hypoxic-ischemic-encephalopathy-market-disease-emerging-therapy-and-market-report-2032_586036.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[406],"tags":[],"class_list":["post-586036","post","type-post","status-publish","format-standard","hentry","category-Pharmaceuticals-Biotech"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/586036","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=586036"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/586036\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=586036"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=586036"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=586036"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}